NCT04235205已完成2 期
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Patients With Nonalcoholic Fatty Liver Disease: a Single Center, Double-blind, Randomized, Placebo-Controlled, Phase 2a Trial.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 102
- 试验地点
- 1
- 主要终点
- Absolute change from baseline in serum LDL-C at Week 16
研究概览
简要总结
The objective is to evaluate the efficacy and safety of once-daily oral doses of 10 mg elobixibat in combination with 9g cholestyramine powder (cholestyramine 4g) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
详细描述
This is a placebo-controlled, randomized, double-blind, parallel group, comparative study, when patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), are administered elobixibat at 10 mg and cholestyramine powder at 9g( cholestyramine 4g) once daily for 16 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who received adequate explanation about this study and provided written informed consent
- •Patients who are ≥ 20 and < 75 years of age at the time of informed consent
- •Patients who have a current biopsy-confirmed NASH within 8 months of screening or a suspected diagnosis of NAFLD/NASH based on the criteria outlined below:
- •Biopsy-confirmed NASH is defined as histological NASH diagnosis with fibrosis stage F1 through F3 and a NAFLD activity score (NAS) of ≥4 with a score of ≥1 in each of the NAS components below as assessed by a pathologist using the NASH Clinical Research Network criteria:
- •i. Steatosis (scored 0 to 3)
- •ii. Ballooning degeneration (scored 0 to 2)
- •iii. Lobular inflammation (scored 0 to 3)
- •The suspected diagnosis of NAFLD/NASH is based on the following criteria:
- •i. Serum aspartate aminotransferase (AST) ≥20 U/L and alanine aminotransferase (ALT) ≥40 U/L in males or ≥28 U/L in females
- •ii. Waist circumference ≥85 cm in males or ≥90 cm in females
- •iii. Diagnosis of metabolic syndrome having 2 or more of the following 3 risk factors at Screening:
- •Fasting plasma glucose ≥110 mg/dL or undergoing drug treatment for elevated glucose
- •Systolic blood pressure ≥130 mmHg and/or diastolic blood pressure≥85mmHg or undergoing drug treatment for hypertension, or antihypertensive drug treatment in a patient with a history of hypertension
- •Triglycerides (TGs) ≥150 mg/dL or undergoing drug treatment for elevated triglycerides,and/or high-density lipoprotein-cholesterol (HDL-C)<40mg/dL or undergoing drug treatment for reduced HDL-C
- •Screening Magnetic Resonance Imaging (MRI) -Proton Density Fat Fraction (PDFF) with ≥8% liver steatosis
- •Fasting serum low density lipoprotein-cholesterol (LDL-C) >120 mg/dL or undergoing antidyslipidemic drugs
- •Be willing to maintain a stable diet and physical activity throughout the course of the study
- •Exclusion criteria：
- •Women who are pregnant, breastfeeding, possibly pregnant or do not agree to use birth control during the study
- •Body mass index (BMI) <23 kg/m²
- •Magnetic Resonance Elastography (MRE) value >6.7 kPa
- •Any of the following laboratory abnormalities:
- •ALT >5 × upper limit normal (ULN) or AST >5 × ULN
- •Prothrombin time - international normalized ratio (PT-INR) ≥1.3 unless on anticoagulant therapy
- •Total bilirubin > ULN, except with an established diagnosis of Gilbert's syndrome
- •Platelet count < 80,000/μL
- •eGFR <45 as calculated by the body surface area (BSA) adjustment (normalized eGFR)
- •Acute or chronic liver disease other than NAFLD/NASH including but not limited to the following:
- •Hepatitis B (as defined by the presence of hepatitis B surface [HBs] antigen at Screening) or hepatitis C(as defined by the presence of hepatitis C virus [HCV] antibody [anti-HCV]) Patients with positive anti-HCV who test negative for HCV ribonucleic acid (HCV-RNA) at Screening will be allowed to participate in the study as long as there is evidence of viral negativity for a minimum of 12 months prior to Screening
- •Evidence of autoimmune hepatitis
- •History of primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, alpha-1-anti-trypsin deficiency, hemochromatosis or iron overload, drug-induced or alcoholic liver disease, or known bile duct obstruction.
- •Suspected or proven hepatocellular carcinoma
- •Known history of human immunodeficiency virus (HIV)
- •Medical history of liver cirrhosis
- •Clinical evidence of portal hypertension to include any history of ascites, hepatic encephalopathy, or presence of esophageal varices
- •Use of drugs historically associated with NAFLD (amiodarone, methotrexate, systemic glucocorticoids, tetracyclines,tamoxifen, estrogens at doses greater than those used for hormone replacement, anabolic steroids, or valproic acid) or other known hepatotoxins for ≥2 weeks in the year prior to Screening
- •Use of the following medications:
- •Glucagon-like peptide-1 (GLP-1) agonists unless on a stable dose 3 months prior to Screening or liver biopsy
- •Ursodeoxycholic acid or thiazolidinediones within 3 months prior to Screening
- •Antidyslipidemic drugs have been stable for ≥3 months prior to Screening
- •Oral antidiabetic drugs have been stable for ≥3 months prior to Screening
- •Agents (including herbal over-the-counter weight loss preparations) or medications known to significantly impact body weight within 3 months prior to Screening
- •History of significant alcohol consumption, defined as an average of≥20g/day in female patients and ≥30 g/day in male patients, for a period of >3 consecutive months within 1 year prior to Screening, hazardous alcohol use (Alcohol Use Disorders Identification Test score ≥8), or an inability to reliably quantify alcohol consumption but determined as alcohol polydipsia based upon judgment of the Investigator or subinvestigator
- •Weight change ≥10% within the 6 months prior to Screening or ≥5% within the 3 months prior to Screening
- •Surgery planned during the study period or after bariatric surgery (e.g., gastroplasty and roux-en-Y gastric bypass)
- •Type 1 diabetes by medical history
- •Uncontrolled Type 2 diabetes defined as hemoglobin A1c (HbA1c) >9.5% at Screening(patients with HbA1c >9.5% may be rescreened) or requiring insulin dose adjustment >10% within 2 months prior to Screening
- •Clinical hyperthyroidism or hypothyroidism or Screening hormone results pointing to thyroid dysfunction. Patients receiving dose-stable thyroid replacement therapy for ≥3 months prior to Screening will be allowed to participate in this study as long as thyroid tests show that the patient is euthyroid and stable
- •History of any condition causing malabsorption such as chronic pancreatitis, extensive bowel/small intestine surgery, celiac disease, or bile flow obstruction
- •History of any condition associated with acute or chronic diarrhea such as inflammatory bowel disease (IBD),functional diarrhea, irritable bowel syndrome (IBS) with predominant diarrhea, IBS with mixed bowel habits, or unclassified IBS
- 另有 8 项未显示
排除标准
- 未提供
研究组 & 干预措施
Elobixibat and cholestyramine
Experimental
The investigational product per dosing (elobixibat 10mg and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
干预措施: Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) (Drug)
Elobixibat
Experimental
The investigational product per dosing (elobixibat 10mg and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
干预措施: Elobixibat 10mg + cholestyramine powder placebo (Drug)
cholestyramine
Experimental
The investigational product per dosing (elobixibat placebo and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
干预措施: Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g) (Drug)
Placebo
Placebo Comparator
The investigational product per dosing (elobixibat placebo and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
干预措施: Elobixibat placebo + cholestyramine powder placebo (Drug)
结局指标
主要结局
Absolute change from baseline in serum LDL-C at Week 16
时间窗: Week 16
Serum
次要结局
- Absolute change from baseline to Week 16 in the liver fat fraction (%) as measured by MRI-PDFF(Week 16)
- Change from baseline to Week 16 in ALT level(Week 16)
- Change from baseline to Week 16 in γ-GTP level(Week 16)
- Absolute change from baseline to Week 16 in HDL-C level(Week 16)
- Absolute change from baseline to Week 16 in hepatic fibrosis as measured by MRE(Week 16)
- Change from baseline to Week 16 in AST level(Week 16)
- Change from baseline to Week 16 in non HDL-C level(Week 16)
- Change from baseline to Week 16 in LDL-C/HDL-C ratio(Week 16)
- Change from baseline to Week 16 in TG level(Week 16)
研究者
Takaomi Kessoku
Department of palliative care center
Yokohama City University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver DiseaseJPRN-jRCT2080225028Takaomi Kessoku100
已完成
Unknown
Examination of efficacy and safety of elobixibat in patients with chronic constipation by combination with or switching from existing therapy - A Retrospective Observational StudyChronic ConstipationJPRN-UMIN000049639Osaka Saiseikai Nakatsu Hospital300
进行中（未招募）
3 期
Elobixibat plus sodium picosulfate with magnesium citrate for bowel preparatioJPRN-jRCTs041210067Hotta Kinichi540
招募中
4 期
Long-term Elobixibat for Chronic ConstipationChronic ConstipationNCT04784780Yokohama City University100
已完成
2 期
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASHNAFLDNASHNCT04006145Albireo47